Atherosclerosis and Hyperlipidemia Research

Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.

Atherosclerosis and Hyperlipidemia Research Products Targets

Products for Atherosclerosis and Hyperlipidemia Research - Page 22

Cat.No. Product Name Information/Activity
BCC7260 RS 102895 hydrochloride RS102895 hydrochloride is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1.
BCC1910 RS 504393 RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
BCC6129 SB 297006 SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.
BCC6056 SB 328437 247580-43-4
BCC6057 Teijin compound 1 CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM.
BCC4447 Plerixafor 8HCl (AMD3100 8HCl) Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
BCC5182 AMD 3465 hexahydrobromide AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
BCC6366 CTCE 9908 1030384-98-5
BCC7917 FC 131 606968-52-9
BCC6234 IT1t dihydrochloride IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.